Pramipexole is a non-ergot dopamine agonist that selectively stimulates dopamine D2, D3, and D4 receptors in the brain. It is a first-line treatment for Parkinson's disease (PD) and is also approved for Restless Legs Syndrome (RLS). The 0.375mg strength is a common therapeutic dose for PD, often used in the initial titration phase. It helps manage motor symptoms like bradykinesia, rigidity, and tremor by compensating for the dopamine deficiency in the nigrostriatal pathway.
Adult: Parkinson's Disease: Start at 0.125 mg TID. Titrate weekly by 0.125 mg TID to effective dose. Usual therapeutic range: 1.5-4.5 mg/day in 3 divided doses. RLS: Start at 0.125 mg once daily, 2-3 hours before bedtime. Titrate to 0.375 mg daily if needed after 4-7 days.
Note: Take orally with or without food. Taking with food may reduce nausea. For RLS, take once daily 2-3 hours before bedtime. Do not crush or chew extended-release tablets (if applicable; 0.375mg is typically immediate-release). Swallow whole with water. Maintain a consistent dosing schedule.
Pramipexole exerts its therapeutic effects by directly stimulating postsynaptic dopamine receptors (D2 subfamily: D2, D3, D4) in the striatum. This action compensates for the depleted dopamine levels characteristic of Parkinson's disease, thereby improving motor function. For RLS, its mechanism is believed to involve modulation of dopaminergic pathways in the spinal cord and brain.
Pregnancy: Category C. Animal studies showed adverse effects. No adequate human studies. Use only if potential benefit justifies potential fetal risk. Consider discontinuing if pregnancy is detected, as safety during labor/delivery is unknown.
Driving: Warn patients about potential for sudden sleep onset (sleep attacks), dizziness, and syncope. Advise not to drive or operate machinery until they know how the medication affects them.
| Levodopa/Carbidopa | Increased dopaminergic effects and side effects (dyskinesia, nausea, hallucinations). Pramipexole may allow reduction of levodopa dose. | Major |
| Antipsychotics (e.g., Haloperidol, Risperidone) | Antagonism of dopaminergic effect, reducing efficacy of pramipexole. | Major |
| Metoclopramide, Domperidone | Domperidone (peripheral blocker) is safer. Metoclopramide (central D2 antagonist) may antagonize pramipexole's effect. | Moderate |
| Antihypertensives | Additive hypotensive effect, increasing risk of dizziness and syncope. | Moderate |
| Cimetidine | Reduces renal clearance of pramipexole by inhibiting tubular secretion, increasing pramipexole AUC by ~50%. Dose adjustment may be needed. | Moderate |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedative effects, increasing risk of somnolence and sleep attacks. | Major |
| Drugs eliminated via active renal secretion (e.g., Amantadine, Cimetidine, Ranitidine) | Potential for competition, altering plasma levels of either drug. | Moderate |